To determine the group II phospholipase A2 (PLA2) content of tears in patients with senile cataract or primary open-angle glaucoma (POAG) and to compare it with the PLA2 content of tears in age-matched healthy controls.
Methods
The PLA2 concentration of tears was measured with time-resolved fluoroimmunoassay in 21 patients with senile cataract, 23 patients with POAG and in 40 healthy controls.
Results
The PLA2 content of tears was 38.3 ± 30.1 μg/ml in patients with senile cataract, 32.1 ± 22.3 μg/ml in patients with POAG, and 36.6 ± 31.1 μg/ml in healthy controls. There were no significant differences between the patient and the control groups.
Conclusions
We conclude that neither senile cataract nor POAG has any effect on the PLA2 content of tears.
ScheuerW.. Phospholipase A2 - Regulation and inhibition.Klin Wochenschr1989; 67: 153–9.
2.
PruzanskiW., WadasP.. Phospholipase A2 - a mediator between proximal and distal effectors of inflammation.Immunology Today1991; 12: 143–6.
3.
NevalainenT.J.. Serum phospholipases A2 in inflammatory diseasesClin Chem1993; 39: 2453–9.
4.
ClarkJ.D., LinL-L, KrizR.W., RameshaC.S., SultzmanL.A., LinA.Y., MilonaN., KnopfJ.L.. A novel arachidonic acid-selective cytosolic PLA2 contains a CA2+-dependent translocation domain with homology to PKC and GAP.Cell1991; 65: 1043–51.
5.
KramerR.M., HessionC., JohansenB., HayesG., McGrayP., ChowE.P., TizardR., PepinskyR.B.. Structure and properties of a human non-pancreatic phospholipase A2.J Biol Chem1989; 264: 5768–75.
6.
SeilhamerJ.J., PruzanskiW., VadasP., PlantS., MillerJ.A., KlossJ., JohnsonL.K.. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid.J Biol Chem1989; 264: 5335–8.
7.
HeinriksonR.L., KruegerE.T., KeimP.S.. Amino acid sequence of phospholipase A2-α from the venom of Cro-talus adamanteus: A new classification of phospholipases A2 based upon structural determinants.J Biol Chem1977; 252: 4913–21.
8.
van den BoschH., AarsmanA.J., van SchaikR.H.N., SchalkwijkC.G., NeijsF.W., SturkA.. Structural and enzymological properties of cellular phospholipases A2.Biochem Soc Trans1990; 18: 781–5.
9.
NevalainenT.J., HaapanenT.J.. Distribution of pancreatic (group I) and synovial-type (group II) phospholipases A2 in human tissues.Inflammation1993; 17: 453–64.
10.
NevalainenT.J., AhoH.J., PeuravuoriH.. Secretion of group 2 phospholipase A2 by lacrimal glands.Invest Ophthalmol Vis Sci1994; 35: 417–21.
11.
AhoH.J., SaariK.M., KallajokiM., NevalainenT.J.. Synthesis of group II phospholipase A2 and lysozyme in lacrimal glands.Invest Ophthalmol Vis Sci1996; 37: 1826–32.
12.
SaariK.M., AhoV.V., PaavilainenV., NevalainenT.J.. Group II phospholipase A2 content of tears in normal subjects.Invest Ophthalmol Vis Sci2001; 42: 318–20.
13.
QuX-D, LehrerR.J.. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears.Infection Immunity.1998; 66: 2791–7.
14.
SongC.H., ChoiJ.S., KimD.K., KimJ.C.. Enhanced secretory group II PLA2 activity in the tears of chronic blepharitis patients.Invest Ophthalmol Vis Sci1999; 40: 2744–8.
15.
NevalainenT.J., KortesuoP.T., RintalaE., MarkiF.. Immunochemical detection of group 1 and group 2 phospholipases A2 in human serum.Clin Chem1992; 38: 1824–9.
16.
SaariK.M., Saaren-SeppalaH., Guillén-MonterrubioO., HartikainenJ., NevalainenT.J.. Phospholipase A2 content of aqueous humor in cataract patients.Acta Ophthalmol Scand1995; 73: 145–7.
17.
CenedellaR.J.. Regional distribution of lipids and phospholipase A2 activity in normal and cataractous rat lens.Curr Eye Res1985; 4: 113–20.
18.
BazanN.G., AllanG.. Signal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids.Surv Ophthalmol1997; 41: 23–34.
19.
SnyderF.. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes.Biochim Biophys Acta1995; 1254: 231–49.
20.
JagerG.V., van DelftJ.L., van HaeringenN.J.Antagonist of platelet-activating factor prevents prostaglandin E2-induced ocular hypertension in rabbits.Prostaglandins1992; 45: 97–105.
21.
MarcheselliV.L., PanettaT., BraquetP.Effects of platelet-activating factor antagonist (BN 52021) on cerebral lipid metabolism following ischemia reperfusion in the gerbil.Ann New York Acad Sci1989; 559: 468–70.
22.
MarcheselliV.L., BazanN.G.. Platelet-activating factor (PAF) enhances glutamic acid release in the retina through a presynaptic receptor.Invest Ophthalmol Vis Sci1993; 34: 1048.
23.
SchumerR.A., PodosS.M.. The nerve of glaucoma.Arch Ophthalmol1994; 112: 37–44.
